The University of Southampton
University of Southampton Institutional Repository

Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results

Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results
Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results

Purpose: the role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial. 

Methods: the IELSG37 trial, a randomized noninferiority study, aimed to assess whether irradiation can be omitted in patients with PMBCL with complete metabolic response (CMR) after induction immunochemotherapy. The primary end point was progression-free survival (PFS) at 30 months after random assignment. Patients with CMR were randomly assigned to observation or consolidation radiotherapy (30 Gy). With a noninferiority margin of 10% (assuming a 30-month PFS of 85% in both arms), a sample size of 540 patients was planned with 376 expected to be randomly assigned.

Results: the observed events were considerably lower than expected; therefore, primary end point analysis was conducted when ≥95% of patients were followed for ≥30 months. Of the 545 patients enrolled, 268 were in CMR after induction and were randomly assigned to observation (n = 132) or radiotherapy (n = 136). The 30-month PFS was 96.2% in the observation arm and 98.5% in the radiotherapy arm, with a stratified hazard ratio of 1.47 (95% CI, 0.34 to 6.28) and absolute risk difference of 0.68% (95% CI, -0.97 to 7.46). The 5-year overall survival (OS) was 99% in both arms. Nonrandomized patients were managed according to local policies. Radiotherapy was the only treatment in 86% of those with Deauville score (DS) 4 and in 57% of those with DS 5. The 5-year PFS and OS of patients with DS 4 (95.8% and 97.5%, respectively) were not significantly different from those of randomly assigned patients. Patients with DS5 had significantly poorer 5-year PFS and OS (60.3% and 74.6%, respectively).

Conclusion: this study, the largest randomized trial of radiotherapy in PMBCL, demonstrated favorable outcomes in patients achieving CMR with no survival impairment for those omitting irradiation.

1527-7755
JCO2401373
Martelli, Maurizio
32f72970-6db0-45ec-9246-6d074b504192
Ceriani, Luca
5767bf0b-1df0-4479-90df-a3e0beb1c8b8
Ciccone, Giovannino
1dce2e69-91ac-486c-b3e5-a1e14e8e9e96
Ricardi, Umberto
faf727fc-7cd6-4ab0-8a76-b3f063de031b
Kriachok, Iryna
65124bb5-41e3-47a2-a60a-78c5db423cbb
Botto, Barbara
b7cc807b-0896-4175-b96d-db92da55017a
Balzarotti, Monica
e63fea66-73b5-4332-bf18-ba9555b1c0ce
Tucci, Alessandra
09587f59-4d04-49ae-a82a-cb5ae9be5ad8
Usai, Sara Veronica
c77e6bc8-6dce-4933-9b09-cfe960c6f3ce
Zilioli, Vittorio Ruggero
c251857d-ef73-4e12-9aff-cef670217225
Pennese, Elsa
a77168f4-c08a-4b32-bfaf-d0be5fab5d34
Arcaini, Luca
e3e9186c-2630-460f-9116-cde55ad8b625
Dabrowska-Iwanicka, Anna
98e766a1-ade7-4f12-86fd-0576f70650c6
Ferreri, Andrés Jm
7fc33f57-299b-4a1b-9623-b352878d2a09
Merli, Francesco
2458f37d-011d-41d0-af5f-262c6a40b161
Zhao, Weili
7a0c6c01-edd2-4713-a8dc-77a828951870
Rigacci, Luigi
6597586e-7cbd-4074-b7c9-ef2db97d7844
Cellini, Claudia
367a902e-52e8-481a-9744-4a232f4f228c
Hodgson, David
ec5650c7-4538-4352-88f9-ac2fab887ac0
Ionescu, Codruta
7f31bd36-6a75-4eb1-9443-cdf3bf68c684
Minoia, Carla
902bb9bf-02b6-463a-824a-11249dbc71bd
Lucchini, Elisa
107f329e-6bb2-4ae4-8ccf-d979125cbd94
Spina, Michele
c8f19c73-f81d-4871-b0f4-5eeece6656cd
Fosså, Alexander
a2bf2dfe-51f0-409a-a63e-678ea93ebb3a
Janikova, Andrea
44e6d937-d120-4017-ac82-f317d1f2ab07
Cwynarski, Kate
724d6022-f622-403e-83a3-3588db6e25c1
Mikhaeel, George
4ad25227-1c10-4c92-b4de-4555e83d5073
Jerkeman, Mats
52d57011-f86b-4986-a607-998b628d074a
Di Rocco, Alice
39899c86-ad50-40cd-be74-290e64df1cd2
Stepanishyna, Yana
ecc2eec6-32f5-4385-b68f-1c5a1b5d843d
Vitolo, Umberto
e4fa4bb8-b358-4a55-bc3b-3d0d8f48bf44
Santoro, Armando
c608c423-b2a8-4a23-aa42-3c77e48d4fa3
Re, Alessandro
e5001e5a-3f43-4337-9d42-44684310d0a0
Puccini, Benedetta
18cd131d-de10-4a3b-bd1b-096d007eafb8
Olivieri, Jacopo
7b29f8f1-0436-4ba2-8f6f-5f9dae7589fa
Petrucci, Luigi
ef19ea3d-80be-42d2-8cf7-2e5c1fccf76f
Barrington, Sally F
fb047bda-27e7-4082-b741-c41ef52aa53c
Malkowski, Bogdan
70b51304-20e7-4247-b1fa-d848876bbe5e
Metser, Ur
3ceead4b-2f91-42d6-87cb-68cbc48a293e
Versari, Annibale
64a16bae-ea36-4859-83e6-9af2169847a6
Chauvie, Stephane
1efbf22f-a53c-4e57-b9b6-7d2541f3c134
Walewski, Jan
1dd0b2ec-55df-4687-bdac-f8b76dcee139
Trneny, Marek
8ff25181-a331-4dd3-8509-438c66b4d28f
Cavalli, Franco
ce699517-7deb-4bad-8b14-afe749884b9e
Gospodarowicz, Mary
ede5f0fe-46a2-480c-9e98-411b37ac28b8
Johnson, Peter W.M.
1afe5cab-d45a-4cfe-91d9-d212e03cf1f2
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Zucca, Emanuele
40bd5950-d74e-4169-a2ea-0bfc1058058e
International Extranodal Lymphoma Study Group (IELSG)
Martelli, Maurizio
32f72970-6db0-45ec-9246-6d074b504192
Ceriani, Luca
5767bf0b-1df0-4479-90df-a3e0beb1c8b8
Ciccone, Giovannino
1dce2e69-91ac-486c-b3e5-a1e14e8e9e96
Ricardi, Umberto
faf727fc-7cd6-4ab0-8a76-b3f063de031b
Kriachok, Iryna
65124bb5-41e3-47a2-a60a-78c5db423cbb
Botto, Barbara
b7cc807b-0896-4175-b96d-db92da55017a
Balzarotti, Monica
e63fea66-73b5-4332-bf18-ba9555b1c0ce
Tucci, Alessandra
09587f59-4d04-49ae-a82a-cb5ae9be5ad8
Usai, Sara Veronica
c77e6bc8-6dce-4933-9b09-cfe960c6f3ce
Zilioli, Vittorio Ruggero
c251857d-ef73-4e12-9aff-cef670217225
Pennese, Elsa
a77168f4-c08a-4b32-bfaf-d0be5fab5d34
Arcaini, Luca
e3e9186c-2630-460f-9116-cde55ad8b625
Dabrowska-Iwanicka, Anna
98e766a1-ade7-4f12-86fd-0576f70650c6
Ferreri, Andrés Jm
7fc33f57-299b-4a1b-9623-b352878d2a09
Merli, Francesco
2458f37d-011d-41d0-af5f-262c6a40b161
Zhao, Weili
7a0c6c01-edd2-4713-a8dc-77a828951870
Rigacci, Luigi
6597586e-7cbd-4074-b7c9-ef2db97d7844
Cellini, Claudia
367a902e-52e8-481a-9744-4a232f4f228c
Hodgson, David
ec5650c7-4538-4352-88f9-ac2fab887ac0
Ionescu, Codruta
7f31bd36-6a75-4eb1-9443-cdf3bf68c684
Minoia, Carla
902bb9bf-02b6-463a-824a-11249dbc71bd
Lucchini, Elisa
107f329e-6bb2-4ae4-8ccf-d979125cbd94
Spina, Michele
c8f19c73-f81d-4871-b0f4-5eeece6656cd
Fosså, Alexander
a2bf2dfe-51f0-409a-a63e-678ea93ebb3a
Janikova, Andrea
44e6d937-d120-4017-ac82-f317d1f2ab07
Cwynarski, Kate
724d6022-f622-403e-83a3-3588db6e25c1
Mikhaeel, George
4ad25227-1c10-4c92-b4de-4555e83d5073
Jerkeman, Mats
52d57011-f86b-4986-a607-998b628d074a
Di Rocco, Alice
39899c86-ad50-40cd-be74-290e64df1cd2
Stepanishyna, Yana
ecc2eec6-32f5-4385-b68f-1c5a1b5d843d
Vitolo, Umberto
e4fa4bb8-b358-4a55-bc3b-3d0d8f48bf44
Santoro, Armando
c608c423-b2a8-4a23-aa42-3c77e48d4fa3
Re, Alessandro
e5001e5a-3f43-4337-9d42-44684310d0a0
Puccini, Benedetta
18cd131d-de10-4a3b-bd1b-096d007eafb8
Olivieri, Jacopo
7b29f8f1-0436-4ba2-8f6f-5f9dae7589fa
Petrucci, Luigi
ef19ea3d-80be-42d2-8cf7-2e5c1fccf76f
Barrington, Sally F
fb047bda-27e7-4082-b741-c41ef52aa53c
Malkowski, Bogdan
70b51304-20e7-4247-b1fa-d848876bbe5e
Metser, Ur
3ceead4b-2f91-42d6-87cb-68cbc48a293e
Versari, Annibale
64a16bae-ea36-4859-83e6-9af2169847a6
Chauvie, Stephane
1efbf22f-a53c-4e57-b9b6-7d2541f3c134
Walewski, Jan
1dd0b2ec-55df-4687-bdac-f8b76dcee139
Trneny, Marek
8ff25181-a331-4dd3-8509-438c66b4d28f
Cavalli, Franco
ce699517-7deb-4bad-8b14-afe749884b9e
Gospodarowicz, Mary
ede5f0fe-46a2-480c-9e98-411b37ac28b8
Johnson, Peter W.M.
1afe5cab-d45a-4cfe-91d9-d212e03cf1f2
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Zucca, Emanuele
40bd5950-d74e-4169-a2ea-0bfc1058058e

Martelli, Maurizio, Ceriani, Luca and Ciccone, Giovannino , International Extranodal Lymphoma Study Group (IELSG) (2024) Omission of radiotherapy in primary mediastinal B-cell lymphoma: IELSG37 trial results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42 (34), JCO2401373. (doi:10.1200/JCO-24-01373).

Record type: Article

Abstract

Purpose: the role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial. 

Methods: the IELSG37 trial, a randomized noninferiority study, aimed to assess whether irradiation can be omitted in patients with PMBCL with complete metabolic response (CMR) after induction immunochemotherapy. The primary end point was progression-free survival (PFS) at 30 months after random assignment. Patients with CMR were randomly assigned to observation or consolidation radiotherapy (30 Gy). With a noninferiority margin of 10% (assuming a 30-month PFS of 85% in both arms), a sample size of 540 patients was planned with 376 expected to be randomly assigned.

Results: the observed events were considerably lower than expected; therefore, primary end point analysis was conducted when ≥95% of patients were followed for ≥30 months. Of the 545 patients enrolled, 268 were in CMR after induction and were randomly assigned to observation (n = 132) or radiotherapy (n = 136). The 30-month PFS was 96.2% in the observation arm and 98.5% in the radiotherapy arm, with a stratified hazard ratio of 1.47 (95% CI, 0.34 to 6.28) and absolute risk difference of 0.68% (95% CI, -0.97 to 7.46). The 5-year overall survival (OS) was 99% in both arms. Nonrandomized patients were managed according to local policies. Radiotherapy was the only treatment in 86% of those with Deauville score (DS) 4 and in 57% of those with DS 5. The 5-year PFS and OS of patients with DS 4 (95.8% and 97.5%, respectively) were not significantly different from those of randomly assigned patients. Patients with DS5 had significantly poorer 5-year PFS and OS (60.3% and 74.6%, respectively).

Conclusion: this study, the largest randomized trial of radiotherapy in PMBCL, demonstrated favorable outcomes in patients achieving CMR with no survival impairment for those omitting irradiation.

Text
Martelli et al. IELSG37 manuscript - Accepted Manuscript
Restricted to Repository staff only until 19 August 2025.
Request a copy

More information

e-pub ahead of print date: 19 August 2024

Identifiers

Local EPrints ID: 495226
URI: http://eprints.soton.ac.uk/id/eprint/495226
ISSN: 1527-7755
PURE UUID: f0ef090f-c19f-40b2-a44b-8c9a62fcd01a
ORCID for Andrew Davies: ORCID iD orcid.org/0000-0002-7517-6938

Catalogue record

Date deposited: 01 Nov 2024 18:17
Last modified: 17 Dec 2024 02:42

Export record

Altmetrics

Contributors

Author: Maurizio Martelli
Author: Luca Ceriani
Author: Giovannino Ciccone
Author: Umberto Ricardi
Author: Iryna Kriachok
Author: Barbara Botto
Author: Monica Balzarotti
Author: Alessandra Tucci
Author: Sara Veronica Usai
Author: Vittorio Ruggero Zilioli
Author: Elsa Pennese
Author: Luca Arcaini
Author: Anna Dabrowska-Iwanicka
Author: Andrés Jm Ferreri
Author: Francesco Merli
Author: Weili Zhao
Author: Luigi Rigacci
Author: Claudia Cellini
Author: David Hodgson
Author: Codruta Ionescu
Author: Carla Minoia
Author: Elisa Lucchini
Author: Michele Spina
Author: Alexander Fosså
Author: Andrea Janikova
Author: Kate Cwynarski
Author: George Mikhaeel
Author: Mats Jerkeman
Author: Alice Di Rocco
Author: Yana Stepanishyna
Author: Umberto Vitolo
Author: Armando Santoro
Author: Alessandro Re
Author: Benedetta Puccini
Author: Jacopo Olivieri
Author: Luigi Petrucci
Author: Sally F Barrington
Author: Bogdan Malkowski
Author: Ur Metser
Author: Annibale Versari
Author: Stephane Chauvie
Author: Jan Walewski
Author: Marek Trneny
Author: Franco Cavalli
Author: Mary Gospodarowicz
Author: Peter W.M. Johnson
Author: Andrew Davies ORCID iD
Author: Emanuele Zucca
Corporate Author: International Extranodal Lymphoma Study Group (IELSG)

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×